Qualcomm raises long-term targets as analysts highlight data center, edge AI opportunities
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
Tiziana Life Sciences to present clinical updates at Jefferies healthcare conference
FedEx sum-of-the-parts valuation points to upside as freight spin-off approaches, UBS says
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
Dow Jones pokes ahead after IBM's quantum injection, Nvidia earnings
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
Tiziana Life Sciences price target boosted on foralumab update
MongoDB price target lifted by Bank of America ahead of earnings on execution confidence, Atlas momentum
Tiziana Life Sciences price target boosted on foralumab update
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
Tiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trial
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
S&P and Nasdaq close at record highs on ceasefire optimism and tech strength
Tiziana says intranasal drug shows potential to ease Long COVID “brain fog”
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag
Tiziana says intranasal drug shows potential to ease Long COVID “brain fog”
Tiziana Life Sciences to present Phase 2a MSA study at World Parkinson Congress
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
Ollie’s Bargain Outlet upgrade driven by outlet expansion, margin stability
Hochschild and Fresnillo slip as gold price knocked by Trump speech on Iran
Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging
RH stock tanks as fourth quarter results miss on the top and bottom lines
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging
Dow Jones and Nasdaq futures flat as Nvidia and Salesforce earnings digested
Nasdaq extends gains as AI takes center stage with Nvidia, Salesforce earnings due
Nasdaq makes strides as Nvidia and Salesforce prepare to report
Tiziana reports biomarker gains for nasal MS therapy in progressive disease
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
Tiziana reports biomarker gains for nasal MS therapy in progressive disease
Tiziana Life Sciences (NASDAQ:TLSA) vs. Tectonic Therapeutic (NASDAQ:TECX) Financial Comparison
Tiziana Life Sciences publishes positive study on intranasal MS therapy
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
Tiziana Life Sciences announces closing of oversubscribed $8.8M offering
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
Tiziana Life Sciences unveils registered direct offering of up to $17.6M
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
Tiziana Life Sciences to present at 9th Annual Neurosciences Innovation Forum